2025 연구자 정보 (23 / 654)
※ 컨트롤 + 클릭으로 열별 다중 정렬 가능합니다.
Excel 다운로드
| Author Name | 제1저자 여부 | 교신저자 여부 | Address | ResearcherID | ORCID | Paper Title | WoS Edition | 최상위 JCR(%) | WoS Category | Related Email |
|---|---|---|---|---|---|---|---|---|---|---|
|
Choi, Gwanghyeon (Choi, G) |
Seoul Natl Univ, Bundang Hosp, Coll Med, Dept Internal Med, Seoul, Gyeonggi Do, South Korea |
|
|
[JCR상위 1.7%] AI model using CT-based imaging biomarkers to predict hepatocellular carcinoma in patients with chronic hepatitis B | SCIE | 1.7 | GASTROENTEROLOGY & HEPATOLOGY | pindra@empal.com | ||
|
Choi, Na Ryung (Choi, NR) |
Ewha Womans Univ, Coll Med, Dept Internal Med, Seoul, South Korea |
|
|
[JCR상위 1.7%] AI model using CT-based imaging biomarkers to predict hepatocellular carcinoma in patients with chronic hepatitis B | SCIE | 1.7 | GASTROENTEROLOGY & HEPATOLOGY | pindra@empal.com | ||
|
Chung, Jin Wook (Chung, JW) |
Seoul Natl Univ, Coll Med, Dept Radiol, Seoul, South Korea |
|
|
[JCR상위 1.7%] AI model using CT-based imaging biomarkers to predict hepatocellular carcinoma in patients with chronic hepatitis B | SCIE | 1.7 | GASTROENTEROLOGY & HEPATOLOGY | pindra@empal.com | ||
|
Chung, Sung Won (Chung, SW) |
Univ Ulsan, Asan Liver Ctr, Asan Med Ctr, Coll Med,Div Gastroenterol, Seoul, South Korea |
|
|
[JCR상위 1.7%] AI model using CT-based imaging biomarkers to predict hepatocellular carcinoma in patients with chronic hepatitis B | SCIE | 1.7 | GASTROENTEROLOGY & HEPATOLOGY | pindra@empal.com | ||
|
Danso, Michael A. (Danso, MA) |
|
|
[JCR상위 1.7%] Trastuzumab deruxtecan (T-DXd) plus pertuzumab (P) vs taxane plus trastuzumab plus pertuzumab (THP) for first-line (1L) treatment of patients (pts) with human epidermal growth factor receptor 2-positive (HER2+) advanced/metastatic breast cancer (a/mBC): Interim results from DESTINY-Breast09. | SCIE | 1.7 | ONCOLOGY | ||||
|
De Wit, Ronald (De Wit, R) |
|
|
[JCR상위 1.7%] Additional efficacy and safety outcomes and an exploratory analysis of the impact of pathological complete response (pCR) on long-term outcomes from NIAGARA. | SCIE | 1.7 | ONCOLOGY | ||||
|
Donegan, Sarah E. (Donegan, SE) |
|
|
[JCR상위 1.7%] Additional efficacy and safety outcomes and an exploratory analysis of the impact of pathological complete response (pCR) on long-term outcomes from NIAGARA. | SCIE | 1.7 | ONCOLOGY | ||||
|
Douglas, Mark (Douglas, M) |
Univ Sydney, Westmead Inst Med Res, Sydney, Australia Westmead Hosp, Sydney, Australia |
|
|
[JCR상위 1.7%] Efficacy and safety of elebsiran and pegylated interferon alfa combination therapy versus pegylated interferon alfa in participants with chronic hepatitis B virus infection: follow-up results from the ongoing phase 2, randomized, open-label ENSURE study | SCIE | 1.7 | GASTROENTEROLOGY & HEPATOLOGY | jia_jd@ccmu.edu.cn | ||
|
Drakaki, Alexandra (Drakaki, A) |
|
|
[JCR상위 1.7%] Additional efficacy and safety outcomes and an exploratory analysis of the impact of pathological complete response (pCR) on long-term outcomes from NIAGARA. | SCIE | 1.7 | ONCOLOGY | ||||
|
Font Pous, Albert (Pous, AF) |
|
|
[JCR상위 1.7%] Additional efficacy and safety outcomes and an exploratory analysis of the impact of pathological complete response (pCR) on long-term outcomes from NIAGARA. | SCIE | 1.7 | ONCOLOGY | ||||
|
Galsky, Matthew D. (Galsky, MD) |
제1저자 |
|
|
[JCR상위 1.7%] Additional efficacy and safety outcomes and an exploratory analysis of the impact of pathological complete response (pCR) on long-term outcomes from NIAGARA. | SCIE | 1.7 | ONCOLOGY | |||
|
Han, Seul Ki (Han, SK) |
Yonsei Univ, Wonju Coll Med, Wonju, South Korea Kyungpook Natl Univ, Kyungpook Natl Univ Hosp, Daegu, South Korea |
|
|
[JCR상위 1.7%] Long-term clinical outcomes across biopsy-confirmed steatotic liver disease categories: a multicenter prospective cohort study using merged data | SCIE | 1.7 | GASTROENTEROLOGY & HEPATOLOGY | wonshiri@yahoo.com | ||
|
Herbolsheimer, Pia Maarit (Herbolsheimer, PM) |
|
|
[JCR상위 1.7%] Trastuzumab deruxtecan (T-DXd) plus pertuzumab (P) vs taxane plus trastuzumab plus pertuzumab (THP) for first-line (1L) treatment of patients (pts) with human epidermal growth factor receptor 2-positive (HER2+) advanced/metastatic breast cancer (a/mBC): Interim results from DESTINY-Breast09. | SCIE | 1.7 | ONCOLOGY | ||||
|
Hois, Stephan (Hois, S) |
|
|
[JCR상위 1.7%] Additional efficacy and safety outcomes and an exploratory analysis of the impact of pathological complete response (pCR) on long-term outcomes from NIAGARA. | SCIE | 1.7 | ONCOLOGY | ||||
|
Hu, Peng (Hu, P) |
Chongqing Med Univ, Affiliated Hosp 2, Affiliated Hosp 1, Chongqing, Peoples R China |
|
|
[JCR상위 1.7%] Efficacy and safety of elebsiran and pegylated interferon alfa combination therapy versus pegylated interferon alfa in participants with chronic hepatitis B virus infection: follow-up results from the ongoing phase 2, randomized, open-label ENSURE study | SCIE | 1.7 | GASTROENTEROLOGY & HEPATOLOGY | jia_jd@ccmu.edu.cn |
페이지 이동: